Why the study?
What is the bleeding risk associated with dual antiplatelet therapy versus triple therapy in patients after coronary interventions?
What is the bleeding risk associated with dual antiplatelet therapy versus triple therapy in patients after coronary interventions?
Answers are grounded in this paper and cite their sources.
More potent DAPT may increase bleeding without reducing MACE; leaves open net clinical benefit after coronary interventions.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Harris et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: